Girish Chovatia
Founder
Since then, Ami Lifesciences has grown at an average of 25 percent every year. Today, the company’s international presence spans 60 countries, including the likes of Japan, Russia, the US, and Emerging Economies such as China, Brazil, and Egypt.
Recently, CEO Insights’ Editorial Team got an opportunity to connect with Girish Chovatia, Founder, Ami Lifesciences. In the interaction that followed, Girish shared how Ami Lifesciences is re-shaping the way quality medicines are formulated
and delivered across the globe and a lot more.
Please let us know about Ami Life sciences's impact on the Pharmaceutical industry. What are some of your organization's objectives?
We are a generic API manufacturer, partnering with some of the biggest innovator companies like Sanofi, ABC Pharmaceutics, TRB and Dainippon in Japan. Ami Lifesciences is currently working to formulate products across 11 therapeutic categories, focusing on anti diabetic, Anti Tussive, Anti-Epileptic, Anti-Depressant, Anti-Hyperphosphatemia, Liver disease, respiratory, Anti-vertigo, and many more. We emphasize niche molecules rather than generic ones intending to create expertise in complex generics, with fewer players and greater demand in terms of technological advancement.
I founded Ami Lifesciences, intending to change how quality medicines are delivered to people in need. We operate on the principle of extending our focus and services to maximize our impact on the global pharmaceutical industry. We have spent the last two decades building up our scientific and technological capabilities, research, and manufacturing competencies. And I am pleased to say that we have earned a reputation for being innovative, inventive, and resourceful along the way.
Having a solid experience of more than 25 years in the pharma sector,
Please let us know about Ami Life sciences's impact on the Pharmaceutical industry. What are some of your organization's objectives?
We are a generic API manufacturer, partnering with some of the biggest innovator companies like Sanofi, ABC Pharmaceutics, TRB and Dainippon in Japan. Ami Lifesciences is currently working to formulate products across 11 therapeutic categories, focusing on anti diabetic, Anti Tussive, Anti-Epileptic, Anti-Depressant, Anti-Hyperphosphatemia, Liver disease, respiratory, Anti-vertigo, and many more. We emphasize niche molecules rather than generic ones intending to create expertise in complex generics, with fewer players and greater demand in terms of technological advancement.
Ami Lifesciences is intending to change how quality medicines are delivered to people in need by extending their focus and services to maximize impact on the global pharmaceutical industry
I founded Ami Lifesciences, intending to change how quality medicines are delivered to people in need. We operate on the principle of extending our focus and services to maximize our impact on the global pharmaceutical industry. We have spent the last two decades building up our scientific and technological capabilities, research, and manufacturing competencies. And I am pleased to say that we have earned a reputation for being innovative, inventive, and resourceful along the way.
Having a solid experience of more than 25 years in the pharma sector,
how is your professional experience helping you in your current endeavours?
Being a promoter of a Company having more than two decades of experience in Pharmaceutical & Specialty Chemical marketing at the Domestic & International levels, I have gained the ability to forecast how the market trends will be shortly and adapt to all the changes and turn them into opportunities.
What changes in market behavior do you anticipate in the future, and what opportunities do you foresee?
Indian drugs are being exported to more than 200 countries globally, with the US being the key market. Generic drugs account for 20 percent of the global export in terms of volume, making the country the largest provider of generic medicines globally. I believe there lie vast opportunities in the Indian Pharma sector, and as a pure API manufacturing company, we are among the pioneers in this field.
In your professional journey so far, which are the milestones that bestowed you with utmost satisfaction both as an individual and an entrepreneur?
To make my dream come true by believing in my abilities and starting my venture without compromising my principles and values. Today, I get the satisfaction of employing 1200 talented professionals in our company and feel very happy to see them grow.
At the professional level, I received National Awards for Excellence in Healthcare back in 2016. I was recently awarded as the 'CEO of the Year in the Pharmaceutical Sector' by National Awards, 2021.
A significant milestone for Ami Life sciences is that we will be adding a new biological division this year and inoculating our focus on the development of niche molecules. Our strategy is to focus on high value, low volume molecules. We are in the process of expanding our facilities to cater to the incremental needs of Indian customers.
Being a promoter of a Company having more than two decades of experience in Pharmaceutical & Specialty Chemical marketing at the Domestic & International levels, I have gained the ability to forecast how the market trends will be shortly and adapt to all the changes and turn them into opportunities.
What changes in market behavior do you anticipate in the future, and what opportunities do you foresee?
Indian drugs are being exported to more than 200 countries globally, with the US being the key market. Generic drugs account for 20 percent of the global export in terms of volume, making the country the largest provider of generic medicines globally. I believe there lie vast opportunities in the Indian Pharma sector, and as a pure API manufacturing company, we are among the pioneers in this field.
In your professional journey so far, which are the milestones that bestowed you with utmost satisfaction both as an individual and an entrepreneur?
To make my dream come true by believing in my abilities and starting my venture without compromising my principles and values. Today, I get the satisfaction of employing 1200 talented professionals in our company and feel very happy to see them grow.
At the professional level, I received National Awards for Excellence in Healthcare back in 2016. I was recently awarded as the 'CEO of the Year in the Pharmaceutical Sector' by National Awards, 2021.
A significant milestone for Ami Life sciences is that we will be adding a new biological division this year and inoculating our focus on the development of niche molecules. Our strategy is to focus on high value, low volume molecules. We are in the process of expanding our facilities to cater to the incremental needs of Indian customers.